No Data
Redburn Atlantic Adjusts Price Target on Eli Lilly and Company to $800 From $700, Keeps Neutral Rating
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,190
Monday Market Green Like the Irish, But for How Long: Live Stock News
This Is What Whales Are Betting On Eli Lilly
Eli Lilly and Company (LLY) Is Attracting Investor Attention: Here Is What You Should Know
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Junius Falcon : Buy when back to 720 or even 650. EPS up 70% YoY by 2025, will end up P/E 30+y, but only little growth in 2026, so it would go sideway in mid term.
LLY is diversified drugs, it is safer. NVO needs new drugs than weight loss. If they get out competed in that they are done. Its current EPS growth does support its current P/E